TABLE 2.

MiRNAs involved in the regulation of chemotherapeutic and pharmacological drug treatment resistance in malignant primary brain tumors (MPBTs).

miRNA	Type of tumor	Type of drug	Drug	Gene-target	Mechanism	References
miR-128-3p	Glioblastoma	DNA-targeted drugs	TMZ	c-Met/EMT (c-Met, PDGFRα, Notch1, and Slug)	Reduces the proliferation, invasion, and migration	Zhao C. et al., 2020
miR-186	Glioblastoma	DNA-targeted drugs	Cisplatin	YY1	Inhibits the formation of the GIC phenotype	Li J. et al., 2019
miR-302a	Glioblastoma	Tyrosine kinase inhibitors	Cediranib	PGK1	Decrease glycolysis, cell growth, migration, and invasion	Cardoso et al., 2021
miR-let-7f-1	MB	DNA-targeted drugs	Cisplatin	HMGB1	Inhibit autophagy	Pannuru et al., 2014
miR-29c-3p	MB	DNA-targeted drugs	Cisplatin	Bcl-2/Wnt2	Increase apoptosis	Sun et al., 2020
miR-584-5p	MB	Tubulin inhibitors	Vincristine	HDAC1/eIF4E3	Cause cell cycle arrest, DNA damage, and spindle defects	Abdelfattah et al., 2018
miR-31	MB	DNA-targeted drugs	Ginsenoside Rh2	Wnt/β-catenin	Inhibit the proliferation and migration, and induce apoptosis	Chen et al., 2018
miR-197	Meningioma	DNA-targeted drugs	Quercetin	Bcl-2/Bax	Reduce tumor cell proliferation and increase apoptosis	Hu et al., 2020
miR-34a	Aggressive somatotropinoma	SSAs	Octreotide	cAMP	Antiproliferative effect	Bogner et al., 2020
miR-1299	Aggressive prolactinoma	DA	Bromocriptine	FOXO1	Promotes the synthesis and secretion of prolactin	Dénes et al., 2015

miR, MicroRNA; MB, medulloblastoma; SSAs, somatostatin analogs; DA, dopamine antagonist; TMZ, Temozolomide; EMT, epithelial-mesenchymal transition; PDGFRα, platelet-derived growth factor receptor A; YY1, Yin Yang 1; PGK1, phosphoglycerate kinase 1; HMGB1, high-mobility group protein B1; Bcl-2, B-cell lymphoma-2; Wnt2, wingless-type MMTV integration site family, member 2; HDAC1, histone deacetylase 1; IF4E3, eukaryotic translation initiation factor 4E type 3.